Voyager Therapeutics, Inc. (VYGR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1239057,
    "name": "Voyager Therapeutics, Inc.",
    "stock_name": "Voyager Therapeutics, Inc.",
    "full_name": "Voyager Therapeutics, Inc.",
    "name_url": "stocks-analysis/voyager-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "4.35",
    "chg": 0.58,
    "chgp": "15.38%",
    "dir": 1,
    "prev_price": "3.77",
    "mcapval": "236.30",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US92915B1061",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "982.38 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/voyager-therapeutics-inc-1239057-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Voyager Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/voyager-therapeutics-forms-golden-cross-signaling-potential-bullish-breakout-3617250",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/VoyagerTherapeu_goldencross_3617250.png",
        "date": "2025-10-10 19:14:24",
        "description": "Voyager Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators show a generally positive outlook, with increasing buying pressure. Despite a challenging year, the stock has risen significantly over the past month, outperforming the S&P 500, which may attract investor interest."
      },
      {
        "title": "Is Voyager Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-voyager-therapeutics-inc-technically-bullish-or-bearish-3547457",
        "imagepath": "",
        "date": "2025-09-20 19:55:42",
        "description": "As of 12 September 2025, the technical trend for Voyager Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The weekly RSI indicates bearish momentum, contrasting with a bullish monthly RSI. Moving averages on the daily chart are mildly bearish, and the weekly KST is bullish, but the monthly KST is bearish. Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. Overall, the indicators suggest a lack of strong directional momentum.\n\nIn terms of performance, Voyager Therapeutics has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -20.90% compared to the S&P 500's 12.22%, and a one-year return of -28.01% versus the S&P's 17.14%...."
      },
      {
        "title": "Is Voyager Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-voyager-therapeutics-inc-overvalued-or-undervalued-3543814",
        "imagepath": "",
        "date": "2025-09-20 18:29:24",
        "description": "As of 11 March 2025, the valuation grade for Voyager Therapeutics, Inc. has moved from expensive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 0.72, an EV to EBIT of 0.32, and an EV to EBITDA of 0.34. Comparatively, peers like Agenus, Inc. have a more favorable EV to EBITDA ratio of -6.0607, suggesting that Voyager is underperforming relative to its industry counterparts.\n\nThe stock has shown a mixed performance against the S&P 500, with a 1-week return of 2.40% compared to the index's 1.05%, but it has significantly lagged over longer periods, such as a 1-year return of -28.01% versus 17.14% for the S&P 500. This underperformance reinforces the view that Voyager Therapeutics, Inc. is currently overvalued, particularly in light of its negative return on equity of -31.06%...."
      }
    ],
    "total": 8,
    "sid": "1239057",
    "stock_news_url": "https://www.marketsmojo.com/news/voyager-therapeutics-inc-1239057"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Voyager Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout

2025-10-10 19:14:24

Voyager Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. Technical indicators show a generally positive outlook, with increasing buying pressure. Despite a challenging year, the stock has risen significantly over the past month, outperforming the S&P 500, which may attract investor interest.

Is Voyager Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:55:42

As of 12 September 2025, the technical trend for Voyager Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The weekly RSI indicates bearish momentum, contrasting with a bullish monthly RSI. Moving averages on the daily chart are mildly bearish, and the weekly KST is bullish, but the monthly KST is bearish. Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. Overall, the indicators suggest a lack of strong directional momentum. In terms of performance, Voyager Therapeutics has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -20.90% compared to the S&P 500's 12.22%, and a one-year return of -28.01% versus the S&P's 17.14%....

Is Voyager Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:29:24

As of 11 March 2025, the valuation grade for Voyager Therapeutics, Inc. has moved from expensive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 0.72, an EV to EBIT of 0.32, and an EV to EBITDA of 0.34. Comparatively, peers like Agenus, Inc. have a more favorable EV to EBITDA ratio of -6.0607, suggesting that Voyager is underperforming relative to its industry counterparts. The stock has shown a mixed performance against the S&P 500, with a 1-week return of 2.40% compared to the index's 1.05%, but it has significantly lagged over longer periods, such as a 1-year return of -28.01% versus 17.14% for the S&P 500. This underperformance reinforces the view that Voyager Therapeutics, Inc. is currently overvalued, particularly in light of its negative return on equity of -31.06%....

View All News